Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.
ALK Inhibitor Comparison and CNS Penetration
Key Themes:
Notable Insights:
Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More